NasdaqGS:ONCBiotechs
BeOne Medicines ASCO Data Highlights Oncology Pipeline And Revenue Upside Potential
BeOne Medicines (NasdaqGS:ONC) presented new clinical data at the 2026 ASCO Annual Meeting on multiple oncology programs, including solid tumor candidates and bispecific antibodies.
The company highlighted results for a CDK4 inhibitor in metastatic breast cancer, a B7-H4 targeting antibody drug conjugate in ovarian and breast cancers, and a bispecific antibody in hepatocellular carcinoma.
BeOne also reported positive reimbursement progress in Canada for TEVIMBRA in nasopharyngeal carcinoma...